Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange Detected- Revision: v3.5.0 has been added, replacing Revision: v3.4.3.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check47 days agoChange DetectedThe page shows a revision update from v3.4.1 to v3.4.2, which is a minor maintenance change. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1. No visible changes to study content.SummaryDifference0.0%

- Check76 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3 on the page, a non-functional metadata update that does not affect study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check105 days agoChange DetectedA centralized Locations section is added with state subsections for California, Florida, North Carolina, Pennsylvania, and Texas. The previous standalone state location blocks and the HHS Vulnerability Disclosure link are removed.SummaryDifference0.6%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.